China to 'refine' centralized medicine procurement policies

China will refine its centralized drug procurement policy following a probe into off-patent medicine quality, aiming to enhance evaluations and oversight. The healthcare regulator aims to improve pricing mechanisms and support innovative drug development through a medical insurance catalogue, ensuring public confidence in medications remains high.